MedTrace Logo

Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin

NCT00979056 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2013-11-08

No results posted yet for this study

Summary

The aim of the study is to investigate the efficacy of the prophylactic treatment with rifaximin to prevent travellers diarrhoea.

Conditions

  • Diarrhoea

Interventions

DRUG

Rifaximin

400 mg per day, oral use, maximum duration 28 days

DRUG

Lactose

Coated Tablet, Oral Use

Sponsors & Collaborators

  • Dr. Philipp Zanger, MD MSc DTM

    lead OTHER

Principal Investigators

  • Philipp G. Zanger, MD MSc DTM · Institute of Tropical Medicine, University Hospital of Tübingen

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2012-03-31
Completion
2012-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00979056 on ClinicalTrials.gov